VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
SNNSmith & Nephew plc
$30.04$12.7B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksSNNFinancials

Smith & Nephew plc (SNN) Financials

30Y historyFree accessUpdated daily

Revenue growth reached 7.0% by 2025Q4, though gross margins have compressed to 65.6% from historical peaks near 71%, suggesting ongoing pricing pressure.

SNN Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Sales/Revenue6.18B5.81B5.55B5.21B5.21B4.56B5.14B4.9B4.76B4.67B4.63B4.62B4.35B4.14B4.27B3.96B3.77B3.8B3.37B2.78B2.55B2.39B2.11B1.79B1.58B1.69B1.81B1.75B1.73B1.83B
Revenue Growth %6.34%4.7%6.4%0.06%14.3%-11.25%4.77%2.92%2.06%0.76%0.37%6.11%5.17%-3.11%7.77%5.04%-0.76%12.82%21.23%8.89%6.57%13.75%17.76%13.49%-7.06%-6.45%3.61%0.92%-5.37%15.46%
Cost of Goods Sold1.98B1.76B1.73B1.54B1.54B1.4B1.34B1.3B1.25B1.27B1.14B1.16B1.1B1.07B1.14B1.03B1.03B1.08B994M769M701M642.17M616.25M531.63M509.96M00000
COGS % of Revenue31.99%30.36%31.18%29.53%29.6%30.61%26.04%26.47%26.19%27.24%24.67%25.17%25.28%25.86%26.7%26.02%27.31%28.33%29.5%27.67%27.47%26.82%29.27%29.74%32.37%-----
Gross Profit4.2B4.05B3.82B3.67B3.67B3.16B3.8B3.61B3.52B3.4B3.49B3.46B3.25B3.07B3.13B2.93B2.74B2.72B2.38B2.01B1.85B1.75B1.49B1.26B1.07B1.69B1.81B1.75B1.73B1.83B
Gross Margin %68.01%69.64%68.82%70.47%70.4%69.39%73.96%73.53%73.81%72.76%75.33%74.83%74.72%74.14%73.3%73.98%72.69%71.67%70.5%72.33%72.53%73.18%70.73%70.26%67.63%100%100%100%100%100%
Gross Profit Growth %3.85%5.94%3.92%0.16%15.96%-16.74%5.38%2.53%3.53%-2.69%1.04%6.28%6%-2.01%6.79%6.89%0.66%14.69%18.16%8.59%5.62%17.7%18.54%17.92%-37.15%-6.45%3.61%0.92%-5.37%15.46%
Operating Expenses3.2B3.39B3.39B3.23B3.08B2.87B2.98B2.74B2.58B2.6B2.86B2.71B2.44B2.22B2.27B2.01B2.02B2.08B1.77B1.45B1.34B1.28B1.09B1.52B839.35M1.6B1.65B1.51B1.45B1.52B
OpEx % of Revenue51.74%58.33%61.16%61.84%59.02%62.92%58.1%55.93%54.21%55.6%61.78%58.61%56.1%53.69%53.11%50.76%53.53%54.72%52.42%52.29%52.7%53.54%52.01%84.85%53.29%94.6%90.82%86.44%83.68%82.93%
Selling, General & Admin2.9B2.65B2.6B2.44B2.39B2.56B2.31B2.19B2.15B2.03B2.64B2.13B1.99B1.88B2.1B1.86B1.86B1.8B1.53B1.32B1.21B1.15B975.54M872.14M750.09M00000
SG&A % of Revenue46.93%45.65%46.89%46.69%45.93%56.18%45.04%44.6%45.16%43.39%56.99%46.22%45.64%45.52%49.2%46.95%49.42%47.25%45.41%47.46%47.49%47.87%46.34%48.79%47.62%-----
Research & Development296.69M289M299M345M356M307M292M246M223M230M222M235M231M171M167M151M155M152M142M120M122M127.36M119.29M98.78M74.12M69.3M73.12M71.54M69.27M70.73M
R&D % of Revenue4.8%4.97%5.39%6.62%6.83%6.73%5.68%5.02%4.68%4.93%4.79%5.09%5.31%4.13%3.91%3.81%4.11%4%4.21%4.32%4.78%5.32%5.67%5.53%4.71%4.09%4.04%4.09%4%3.86%
Other Operating Expenses0448M205M0000176M202M239M0191M152M94M000-2M1.55B0000-58.47M15.14M1.53B1.57B1.44B1.38B1.45B
Operating Income1.01B657M425M315M593M295M815M863M934M801M628M749M810M846M862M920M723M630M493M537M422M317.06M321.07M242.73M225.86M214.78M178.43M209.98M269.29M311.5M
Operating Margin %16.27%11.31%7.66%6.04%11.38%6.47%15.86%17.6%19.6%17.16%13.55%16.22%18.62%20.45%20.19%23.22%19.17%16.57%14.63%19.32%16.54%13.24%15.25%13.58%14.34%12.67%9.85%12.01%15.54%17.01%
Operating Income Growth %53.02%54.59%34.92%-46.88%101.02%-63.8%-5.56%-7.6%16.6%27.55%-16.15%-7.53%-4.26%-1.86%-6.3%27.25%14.76%27.79%-8.19%27.25%33.1%-1.25%32.27%7.47%5.16%20.37%-15.02%-22.03%-13.55%23.07%
EBITDA1.58B1.24B952M863M1.16B840M1.33B1.32B1.39B1.28B1.14B1.19B1.19B1.17B1.17B1.21B1.03B917M730M706M602M454.39M464.29M394.78M313.67M293.94M266.27M291.97M336.74M384.29M
EBITDA Margin %25.57%21.29%17.16%16.55%22.18%18.42%25.94%26.86%29.25%27.39%24.58%25.73%27.44%28.28%27.35%30.49%27.44%24.13%21.67%25.4%23.59%18.97%22.05%22.08%19.91%17.34%14.7%16.7%19.44%20.99%
EBITDA Growth %27.7%29.94%10.31%-25.35%37.62%-36.98%1.21%-5.52%8.99%12.29%-4.12%-0.5%2.05%0.17%-3.31%16.71%12.87%25.62%3.4%17.28%32.49%-2.13%17.61%25.86%6.71%10.39%-8.8%-13.29%-12.37%22.27%
D&A (Non-Cash Add-back)574.34M580M527M548M563M545M518M454M460M478M511M439M384M324M306M288M312M287M237M169M180M137.33M143.21M152.05M87.81M79.16M87.84M82M67.45M72.78M
EBIT1.01B657M429M326M679M321M818M852M946M1.13B622M759M823M1.1B867M977M712M635M493M537M506M180M205M242.85M225.86M315.64M270.65M222.52M272.6M323.15M
Net Interest Income-128.3M-149M-105M-66M-74M-56M-55M-51M-61M-62M-39M-23M-7M2M-21M-25M-40M-66M-24M16M2M2M-9M00-10.46M5.5M-2.82M-6.45M-9.76M
Interest Income28.07M19M34M14M6M6M10M8M6M6M11M13M14M11M4M3M2M5M10M19M27M32.22M19.64M006.57M16.66M13.45M14.22M7.36M
Interest Expense156.36M168M139M80M80M62M65M59M67M68M50M36M21M9M12M18M42M71M40M9M18M13M10.71M20.46M017.03M11.16M16.27M20.66M17.13M
Other Income/Expense-224.52M-159M-135M-80M-7M-49M-72M-82M-55M261M-69M-35M-8M246M-21M-25M-53M-66M-24M13M6M2M-132.07M43.83M-15.58M174.52M5.49M683K-17.36M-5.48M
Pretax Income780.82M498M290M235M586M246M743M781M879M1.06B559M714M802M1.1B848M895M670M564M469M550M428M345.83M410.89M290.73M210.28M396.1M294.58M223.26M251.93M306.02M
Pretax Margin %12.64%8.57%5.23%4.51%11.24%5.39%14.46%15.93%18.45%22.75%12.06%15.46%18.43%26.59%19.86%22.59%17.76%14.84%13.92%19.79%16.77%14.44%19.52%16.26%13.35%23.37%16.26%12.77%14.54%16.71%
Income Tax154.36M86M27M12M62M-202M143M118M112M278M149M213M246M371M266M280M198M187M153M156M126M85.55M146.43M105.98M93.2M86.18M125.05M67.72M63.98M99.33M
Effective Tax Rate %19.77%17.27%9.31%5.11%10.58%-82.11%19.25%15.11%12.74%26.18%26.65%29.83%30.67%33.73%31.37%31.28%29.55%33.16%32.62%28.36%29.44%24.74%35.64%36.45%44.32%21.76%42.45%30.33%25.39%32.46%
Net Income626.46M412M263M223M524M448M600M663M767M784M410M501M556M729M582M615M472M377M316M745M333M290.01M264.46M184.75M188.72M309.92M169.54M155.53M187.96M206.7M
Net Margin %10.14%7.09%4.74%4.28%10.05%9.82%11.68%13.52%16.1%16.79%8.85%10.85%12.78%17.62%13.63%15.52%12.51%9.92%9.38%26.81%13.05%12.11%12.56%10.33%11.98%18.29%9.36%8.89%10.85%11.29%
Net Income Growth %52.05%56.65%17.94%-57.44%16.96%-25.33%-9.5%-13.56%-2.17%91.22%-18.16%-9.89%-23.73%25.26%-5.37%30.3%25.2%19.3%-57.58%123.72%14.82%9.66%43.15%-2.11%-39.11%82.81%9%-17.25%-9.07%18.59%
Net Income (Continuing)626.46M412M263M223M524M448M600M663M767M784M410M501M556M721M575M615M472M377M316M394M302M122M133M180.65M117.08M127.09M151.24M155.5M187.96M206.7M
Discontinued Operations000000000000000000000000000000
Minority Interest000000000000000000000000000000
EPS (Diluted)1.440.941.200.501.201.021.361.521.761.760.921.121.221.621.301.381.060.840.681.580.700.560.560.190.200.300.180.170.200.22
EPS Growth %53.19%-21.67%140%-58.33%17.65%-25%-10.53%-13.64%0%91.3%-17.86%-8.2%-24.69%24.62%-5.8%30.19%26.19%23.53%-56.96%125.71%25%0%194.74%-5%-33.33%66.67%5.88%-15%-9.09%15.79%
EPS (Basic)1.460.941.200.501.201.021.381.521.761.760.921.121.241.621.301.381.060.860.681.580.720.560.560.200.200.300.190.170.200.22
Diluted Shares Outstanding436.47M438.3M218.44M437.55M438.86M437.55M437.55M437.55M437.55M446.47M436.45M449.73M453M450.5M447.5M444.5M442.78M445M464M472M471.5M470.5M468M477.12M464.78M437.55M437.55M455.17M455.33M452.06M
Basic Shares Outstanding433.42M438.3M217.75M437.55M438.5M437.55M437.55M437.55M437.55M444.95M437.55M446.5M450.5M448.5M445.5M444M441.95M443M461.5M470.5M465M467.5M465M462.84M460.5M437.55M437.55M454.09M454.1M452.06M
Dividend Payout Ratio52.8%79.37%124.33%146.64%62.79%73.21%53%48.42%35.07%35.59%66.34%49.9%42.99%25.51%25.09%21.46%25.42%28.91%33.23%12.89%27.33%16.21%17.02%37.94%32.41%229.59%----

Key Metrics

Growth RegimeExpanding
ProfitabilityModerate
Balance SheetHealthy
Cash FlowImproving
Top Statement Risk

Margin compression from competition

Revenue Growth Momentum Shows Resilience

As reported in recent financial statements, Smith & Nephew achieved a 7.0% revenue growth rate by 2025Q4, signaling a steady recovery in elective procedure volumes that suggests the company is successfully navigating the competitive landscape while maintaining its core market position across its three primary operating segments.

The acceleration in top-line growth from 3.4% in 2024Q2 to 7.0% by the end of 2025 suggests that the company's focus on clearing surgical backlogs is yielding tangible results. Investors should monitor whether this growth is sustainable or merely a reflection of temporary post-pandemic volume normalization in the orthopaedics segment.

Gross Margin Volatility Warrants Caution

Based on reported figures, the company's gross margin experienced a notable contraction to 65.6% in 2025Q4, down from historical peaks near 71%, which may indicate intensifying pricing pressure or shifts in product mix that could challenge the firm's long-term ability to maintain its premium pricing power.

The decline in gross margin suggests that competitive headwinds, potentially from peers like Stryker, are forcing the company to sacrifice pricing to maintain volume. This trend warrants further investigation into whether the shift toward cementless implants is successfully offsetting the margin erosion seen in traditional reconstruction and trauma lines.

Operating Leverage Remains Under Pressure

According to recent SEC filings, the operating margin reached 17.9% in 2025Q4, yet the persistent reliance on high SG&A spending relative to gross profit suggests that the company has struggled to achieve the operational efficiency gains typically expected from a firm of its scale and market presence.

The high SG&A-to-revenue ratio implies that the company's direct sales force model remains a significant drag on profitability. Unless management can demonstrate a clear path to scaling revenue without a commensurate increase in clinical support costs, operating margins may remain capped below the levels of more efficient U.S.-based peers.

Restructuring Costs Obscure Earnings Quality

As indicated by the income statement data, the company's net income has been subject to significant volatility, with EPS jumping to 0.76 in 2025Q4, a trend that appears heavily influenced by the timing of non-recurring restructuring charges and the ongoing execution of the firm's 12-Point Plan.

The frequent appearance of restructuring costs suggests that the company is in a constant state of operational realignment, which complicates the assessment of true underlying earnings power. Investors should be wary of treating these periodic earnings spikes as indicative of sustainable profitability until the cost base stabilizes.

SNN — Frequently Asked Questions

Quick answers to the most common questions about buying SNN stock.

What was Smith & Nephew plc's (SNN) revenue in 2025?

For fiscal year 2025, Smith & Nephew plc (SNN) reported total revenue of $6.18B. This represents a 237.4% increase compared to $1.83B in 1996.

Is Smith & Nephew plc (SNN) profitable?

Smith & Nephew plc (SNN) is profitable, generating $626.5M in net income for the fiscal year ending 2025 with a net profit margin of 10.1%.

What is Smith & Nephew plc's operating profit margin?

Smith & Nephew plc (SNN) reported an operating income of $1.01B, resulting in an operating profit margin of 16.3%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Smith & Nephew plc's gross profit and gross margin?

Smith & Nephew plc (SNN) generated $4.20B in gross profit for the year, representing a gross profit margin of 68.0%. This demonstrates the company's core pricing power and production efficiency.